학술논문

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.
Document Type
journal article
Source
Annals of the Rheumatic Diseases; Jun2019, Vol. 78 Issue 6, p754-760, 7p, 1 Diagram, 2 Charts, 3 Graphs
Subject
THERAPEUTIC use of monoclonal antibodies
BONE remodeling
SUBCUTANEOUS injections
ANTIRHEUMATIC agents
AUTOANTIBODIES
B cells
GLYCOPROTEINS
INFLAMMATORY mediators
METHOTREXATE
MONOCLONAL antibodies
RHEUMATOID arthritis
STATISTICAL sampling
RANDOMIZED controlled trials
BLIND experiment
SEVERITY of illness index
CHEMICAL inhibitors
Language
ISSN
00034967
Abstract
Copyright of Annals of the Rheumatic Diseases is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)